Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-06
2009-08-11
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
07572795
ABSTRACT:
Compounds having the Formula (I), including pharmaceutically acceptable salts thereof,wherein at least one of X1, X2or X3isand any remaining X1, X2or X3is hydrogen, which are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, A1, A2and m are as described herein.
REFERENCES:
patent: 5658903 (1997-08-01), Adams et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 5945418 (1999-08-01), Bemis et al.
patent: 5977103 (1999-11-01), Adams et al.
patent: 6087496 (2000-07-01), Anantanarayan et al.
patent: 6130235 (2000-10-01), Mavunkel et al.
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6251914 (2001-06-01), Adams et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 2005/0043306 (2005-02-01), Leftheris et al.
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 01/14378 (2001-03-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 01/36420 (2001-05-01), None
patent: WO 01/56358 (2001-08-01), None
patent: WO 03/090912 (2003-11-01), None
patent: WO 03/091229 (2003-11-01), None
patent: WO 2004/009784 (2004-01-01), None
patent: WO 2004/013145 (2004-02-01), None
patent: WO 2004/054514 (2004-07-01), None
patent: WO2004/072030 (2004-08-01), None
patent: WO 2005/028473 (2005-03-01), None
patent: WO 2007/138381 (2007-12-01), None
Kaminska B., Biochimica et Biophysica Acta 1754, 253-262, 2005.
Bundgaard, “Means to Enhance Penetration”, Advanced Drug Delivery Reviews, 1992, 8, 1-38.
Bundgaard, Design of Prodrugs, 1985, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, New York, Oxford.
Henry et al., “p38 Mitogen-Activated Protein Kinase as a Target for Drug Discovery”, Drugs of the Future, 1999, 24 (12) 1345-1354.
Krogsgaard-Larsen et al., A Textbook of Drug Design and Development, 1991, Harwood Academic Publishers GmBH, Poststrasse 22,7000 Chur, Switzerland.
Moreland et al, “Etanercept Therapy in Rheumatoid Arthritis”, Ann. Intern. Med., 1999, 130, 478-486.
Raingeaud et al., “MKK3- and MKK6-Regulated Gene Expression is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Cellular Biology, 1996, 1247-1255.
Rankin et al., “The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, 1995, 34, 334-342.
Salituro et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, 1999, 6, 807-823.
Takahama, U. et al.,FEBS Letters, vol. 518, pp. 116-118 (2002).
C. Pargellis et al,Current Opinion in Investigational Drugs, vol. 4, No. 5, pp. 566-671, 2003.
Alexander, J. et al., Journal of Medicinal Chemistry, American Chemical Soc., vol. 31, No. 2, (1988) pp. 318-322.
Leftheris Katerina
Lin James
Liu Chunjian
Vrudhula Vivekananda M.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Duncan Laurelee A.
LandOfFree
Pyrrolotriazine aniline prodrug compounds useful as kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolotriazine aniline prodrug compounds useful as kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine aniline prodrug compounds useful as kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134549